Pharvaris is a technology company.
Pharvaris has raised $146.0M across 2 funding rounds.
Key people at Pharvaris.
Pharvaris has raised $146.0M in total across 2 funding rounds.
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists, specifically deucrictibant, to prevent and treat hereditary angioedema (HAE) attacks.[1][2] It serves patients with bradykinin-mediated angioedema, including HAE and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), addressing the problem of painful, potentially life-threatening swelling attacks by offering convenient oral alternatives to injections with injectable-like efficacy and placebo-like tolerability.[1][2] The company has shown strong growth momentum with positive Phase 2 data for both prophylactic and on-demand treatments, and is currently enrolling in the pivotal RAPIDe-3 Phase 3 study for on-demand HAE treatment while planning to start the HAE CHAPTER-3 Phase 3 study for prophylaxis by late 2024.[1][2]
Pharvaris emerged from a legacy of expertise in HAE research, driven by a team passionate about advancing treatments for bradykinin-mediated diseases.[2] While specific founders are not detailed in available sources, the company's backstory centers on pioneering science to provide patient choice, building on clinically proven bradykinin B2 receptor targets with novel small molecules.[1][2] Early traction came from successful Phase 2 studies demonstrating efficacy in both prophylaxis and on-demand settings for HAE, paving the way for late-stage development and positioning Pharvaris as a leader in oral HAE therapies.[1]
Pharvaris stands out in the HAE treatment landscape through these key strengths:
Pharvaris rides the trend toward patient-friendly biopharma innovations, particularly in rare diseases like HAE, where current standards rely on injectables that limit adherence and convenience.[1][2] The timing aligns with growing demand for oral therapies in bradykinin-mediated conditions, fueled by market forces such as rising HAE prevalence awareness and biopharma shifts to small-molecule antagonists over biologics.[1] By advancing deucrictibant into Phase 3, Pharvaris influences the ecosystem by challenging injectable dominance, potentially setting new standards for prophylaxis and on-demand treatment, and expanding options for underserved patients.[2]
Pharvaris is poised for potential commercialization with Phase 3 readouts from RAPIDe-3 and HAE CHAPTER-3 expected in the coming years, which could validate its oral HAE platform and drive partnerships or approvals.[1][2] Trends like precision medicine for rare diseases and oral drug delivery advancements will shape its path, amplifying influence as it addresses unmet needs in bradykinin-mediated angioedema. Success here could redefine HAE care, freeing patients from injections while building on its late-stage momentum to lead in this niche.
Key people at Pharvaris.
Pharvaris has raised $146.0M in total across 2 funding rounds.
Pharvaris's investors include Access Biotechnology, General Atlantic, venBio, Vida Ventures, Westlake Village BioPartners, Sean Harper.
Pharvaris has raised $146.0M across 2 funding rounds. Most recently, it raised $80.0M Series C in November 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2020 | $80.0M Series C | Access Biotechnology, General Atlantic, venBio, Vida Ventures, Westlake Village BioPartners, Sean Harper | |
| Sep 1, 2019 | $66.0M Series B | Access Biotechnology, General Atlantic, venBio, Vida Ventures, Westlake Village BioPartners, Sean Harper |
